Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
You just know Crown Royal is jumping at this.
What lies are those surf? Is Brian Gartland a conspirator?
"No, as that page has been up for months with the lies!"
https://briangartlandentertainment.com/hollywood-after-dark/ Disappointed surf? They must still be planning on doing something with this for it to be up on this website. Look at this page...it is displayed prominently with a lot of well know shows; https://briangartlandentertainment.com/
There is no company to contact. The whole thing is a dirty broker run scam and so are you. Only an idiot would contact dirty brokers running a sham.
Herd949
Level Icon
Followers 0
Posts 2
Boards Moderated 0
Alias Born 02/12/2024
It won't take much to move this. You can tell by the shallow volume that has moved the bid/ask from.0001/.0002 to .0002/.0003 repeatedly this winter. If contracts for HAD start getting announced, mwwc will make enormous gains. Hopefully, the silence gets broken with good news.
Who the eff are you bullshitting? A dirty broker threw $20 at the last minute to bullshit everyone. Dirty brokers are so desperate. They must have clients $$$$ tied up in this scam and trying desperately not to take heavy losses.
UEEC
United Health Products, Inc.
Common Stock
0.20115
0.00125
0.63%
0.1862 / 0.2092 (1 x 1)
TRADE DATA
DATE TIMESTAMP PRICE $ CHANGE VOLUME
03/28/2024 15:56:59 0.20115 0.02 100
03/28/2024 14:56:07 0.1841 -0.03 749
Who the eff are you bullshitting? Throw $20 at the last minute to bullshit everyone corrupt clown. You jackasses are so desperate. Do you dirty brokers have your clients $$$$ tied up in this scam and trying not to take heavy losses?
UEEC
United Health Products, Inc.
Common Stock
0.20115
0.00125
0.63%
0.1862 / 0.2092 (1 x 1)
TRADE DATA
DATE TIMESTAMP PRICE $ CHANGE VOLUME
03/28/2024 15:56:59 0.20115 0.02 100
03/28/2024 14:56:07 0.1841 -0.03 749
"Just seen the trailer for the remake of roadhouse. Proves my point exactly, there is no originality left in Hollywood."
"That’s why I’ve had my doubts about HAD. Honestly I don’t think there’s any demand for it."
"Who makes two seasons of a reality show and does zero publicity or promote it on social media. JMHO."
"Tell me where I’m wrong."
Angels; do you volunteer to do the welfare check?
"Looks like Blagman has"
What could possibly go wrong or change between now and then?
"I dont think you can tweet Lionsgate without something actually about to happen with them.... Lawyers would have not allowed him to do the things he is doing unless it was on the up and up. Use some logic."
He just tweeted 2 days ago: March 26
Yup. That's my sense too.
"Of course will get fucked"
"Means NOTHING"
You're just embarrassing yourself pretending this isn't a scam that hoodwinks gullible suckers.
You had full FDA submission in 2017...what's changed?
https://www.otcmarkets.com/filing/html?id=12414685&guid=4td-kaJ6H_M4B3h#UEEC_EX991_HTM
"FDA Selects HemoStyp ® for CtQ Pilot Program
Henderson, Nevada – December 4, 2017 –United Health Products, Inc. (UHP) (OTC: UEEC), manufacturer and marketer of HemoStyp®, a patented hemostatic gauze for the healthcare and wound care sectors, today announced that it is proceeding with its application for HemoStyp under the FDA’s new and innovative CtQ Pilot Program. The FDA selected UHP’s HemoStyp as only one of nine participants for the program. UHP management has scheduled its first face-to-face meeting with FDA experts for January 17, 2018 to provide the agency with whatever information it needs to advance the application for premarket approval (PMA).
The FDA has stated that it intends to work collaboratively with pilot program participants during the review of their PMA submission to define characteristics of the device that are critical to product quality, and how these characteristics are controlled in design and manufacturing prior to the postmarket inspection. For pilot program participants, the FDA would forego conducting the standard PMA preapproval inspection, and a postmarket inspection focusing on the PMA applicant’s implementation of the critical to quality characteristics would be conducted instead.
The CtQ Pilot Program was created to identify products that have a chemical makeup of demonstrated safe interaction with the body –as evidenced by years of prior product usage and studies-- to be approved for Class III internal surgical use. The program’s intent is to allow products that have demonstrated repeated safe interaction to enter the market in a more efficient manner. This application will run simultaneously with the company’s prior Class II application for expanded indication. The market for 2017 internal surgical market for hemostatic products is estimated at in excess of seven billion dollars, and is expected to grow at 7.1% over the next few years, to reach more than $8.3 billion by 2022. (http://industryarc.com/Report/15189/hemostats-market.html)
Concurrent with its CtQ Pilot Program participation, UHP reaffirms that its current Class II application – Expanded Indication submission with the US FDA-- continues to progress, and is in an advanced stage of review
About Premarket Approval Application Critical to Quality (PMA CtQ) Pilot Program
Top-quality medical devices help the FDA better protect and promote public health. And one of the top priorities for FDA’s medical devices center is a focus on quality.
More specifically, the FDA is working with stakeholders—industry, health care providers, patients, payers, and investors—to build a strong Case for Quality.
This program allows the FDA to identify device manufacturers that consistently produce high-quality devices. By doing so, we can better focus our resources helping other manufacturers raise their level of quality. This program also helps the FDA identify and promote practices that support consistent quality manufacturing, and align our regulatory, enforcement, compliance approaches with those practices.
The FDA launched the Case for Quality in 2011 following an in-depth review of device quality data and feedback from both FDA and industry stakeholders. The FDA’s analysis flagged certain widespread or common manufacturing risks that impact product quality. The review also showed manufacturers that focus on and manage those risks often become more productive, receiving fewer complaints, needing to open fewer CAPAs and investigations, and having lower quality-related product costs than their competitors.
In simple terms, the review identified that an investment in quality has long-term payoffs."
Looks like, once again, I am telling the truth. Butler Capital even lists him as working there. I'm just trying to clear things up so the marks for this Ponzi Scheme aren't mislead by pathological sociopaths. Certainly, you understand that, don't you dr5?
Next we visit Butler's website:
Brian Thom
Alternative Asset Sales for Butler Capital and Principal of Waveny Partners, Alternative Asset Management Firm
Previous Experience
Capital Placement Practitioner and Advisor to Corporate Clients for Butler Capital and Principal of Waveny Partners
Head of Corporate Finance for the Americas with Société Générale
Managing Director at FBR & Co. Leading M&A and equity capital raising transactions in the Energy sector
Global Mergers & Acquisitions group at JPMorgan
Master in Business Administration from McMaster University
The link tells a different story. Who should we believe; you or the link? It says Thom is an active broker at Butler Capital Partners.
https://brokercheck.finra.org/individual/summary/4231884
BUTLER CAPITAL PARTNERS (CRD# 114242)
2022 - Present (1 year)
Current Registration(s)
B
BUTLER CAPITAL PARTNERS (CRD#:114242)
151 Post Road Titus House, OLD WESTBURY, NY 11568
Registered with this firm since 11/11/2022
What specifically is not true? Is that not the address UHP gives as "headquarters" on their website? Do these links bother and trouble you? Name every employee and tell us their responsibilities? Tell us what has changed with the PMA's between 2017 and now?
You seem pretty upset for someone who owns stock in a wonderful company that does wonderful business. Why? Can't you just sit back and let the market respond to this wonderful product with wonderful sales? You should be on top of the world being a shareholder as you inform us you are.
This guy right here is in charge?: https://brokercheck.finra.org/individual/summary/4231884
He must be doing a lot as CEO of UHP while sitting behind the desk of a totally different company. And you say Beplate has nothing to do with it? Who picked this stockbroker to be "CEO"?
And at the other end of the country from Thom is UHP headquarters:
526 Commerce Circle, Suite 120 Mesquite, NV 89027
Nice Suite. What a wonderful professional location. It's very accessible. I bet potential clients are really impressed by the selection of u-hauls when they make their way to meet Mr. CEO Brian Thom in the u-haul showroom and discuss business. You can see all the effort into finding business partners at this serious operation. A whole lot of constructive activity must be getting done at UHP. Does Thom do anything besides manipulate the price, regurgitate old PR's with a few words changed, and sell stock? What really has changed? A few names change, like a few words change, in a regurgitated PR? 3 years ago it seems Beplate had over 30 million shares. What happened to them? Why is nothing to do with this so-called company verifiable? I never see any answers into what has changed since the 2017 PMA and now. This whole thing is beyond fishy.
Transaction
Date Reported DateTime Exercisable Expiration Company Symnbol Insider Relationship Shares Traded Conversion Price Shares Owned Filing
2019-11-05 Option Award 2021-08-06 5:22 pm N/A N/A United Health Products Inc. UEEC BEPLATE DOUGLAS K CEO 400,000 $0.97 712,142
(Direct) View
2021-01-06 Option Award 2021-01-11 4:30 pm N/A N/A United Health Products Inc. UEEC BEPLATE DOUGLAS K Director 10% Owner 30,730,000 $0.56 35,805,142 (Direct) View
2020-11-30 Option Award(A) 2020-12-04 5:00 pm N/A N/A United Health Products Inc. UEEC BEPLATE DOUGLAS K Former CEO 40,000 $0 360,000
(Direct) View
2020-11-30 Option Award 2020-12-02 5:00 pm N/A N/A United Health Products Inc. UEEC BEPLATE DOUGLAS K Former CEO 40,000 $0 311,444
(Direct) View
2020-09-30 Option Award 2020-11-20 4:00 pm N/A N/A United Health Products Inc. UEEC BEPLATE DOUGLAS K Chief Executive Officer 147,750 $0 390,000
(Direct) View
2020-07-21 Option Award 2020-07-30 7:46 pm N/A N/A United Health Products Inc. UEEC BEPLATE DOUGLAS K Chief Executive Officer 5,070,000 $0.71 5,075,142
(Direct) View
https://www.secform4.com/insider-trading/1256745.htm
As unthinkable as it is, maybe your word Beplate has nothing to do with this is not very believable. It's just hard to believe someone with so many shares in a non-existent enterprise is not lurking about.
Who is? Is it up for sale?
Are they honest individuals? Can UHP be trusted? It's very relevant Mr. Con Man. And it is the point. Is it intelligent to trust this operation with your hard earned money? Is someone an idiot, as you proclaim, if they do not want to entrust this type of individual with their money?
https://www.sec.gov/files/litigation/complaints/2022/comp25413.pdf
The SEC views these fraudulent actors differently than you. And you have no problem with defrauding shareholders when they are getting conned out of money. But you do have a problem with people, with common sense, pointing out to others what the lowlifes are trying to do with them and their money. UHP might be heroes to you.To the SEC, not so much. Go ahead, keep telling everyone this is business as normal (maybe in a Ponzi Scheme).
"FIRST CLAIM FOR RELIEF
Violations of Exchange Act Section IO(b) and Rule 10b-5 Thereunder
(UHP and Beplate)
SECOND CLAIM FOR RELIEF
Violations of Exchange Act Section I0(b) and Rules IOb-S(a) and (c) Thereunder
(Schiliro)
THIRD CLAIM FOR RELIEF
Aiding and Abetting Violations of Exchange Act Section lO(b) and Rule 10b-5(b)
(Schiliro)
FOURTH CLAIM FOR RELIEF
Violations of Securities Act Section 17(a)
(All Defendants)
FIFTH CLAIM FOR RELIEF
Violations of Exchange Act Section 13(a), 13(b)(2)(A) and 13(b)(2)(B)
of the Exchange Act and Rules 12b-20, 13a-1 and 13a-13 Thereunder
(UHP)
SIXTH CLAIM FOR RELIEF
Aiding and Abetting Violations of Exchange Act Section 13(a),
13(b)(2)(A), 13(b)2)B), and Rules 12b-20, 13a-1 and 13a-13
(Beplate and Schiliro)
SEVENTH CLAIM FOR RELIEF
Violation of Section 13(b)(5) of the Exchange Act and Exchange Act Rule 13b2-1
(Beplate and Schiliro)
EIGHTH CLAIM FOR RELIEF
Violations of Exchange Act Section 13(a) and Rule 13a-14 Thereunder
(Beplate)
NINTH CLAIM FOR RELIEF
Violations of Rule 13b2-2 of the Exchange Act
(Beplate and Schiliro)
TENTH CLAIM FOR RELIEF
Violations of Sarbanes-Oxley Act Section 304(a)
(Beplate)
ELEVENTH CLAIM FOR RELIEF
Violations of Exchange Act Section 16(a) and Rule 16a-3 Thereunder
(Beplate)
What happened with the 2017 submission? It's relevant. https://www.otcmarkets.com/filing/html?id=12414685&guid=4td-kaJ6H_M4B3h#UEEC_EX991_HTM
Nothing could be more relevant than what happened. Only a complete fool would pass this off (which is what you fish for).
"FDA Selects HemoStyp ® for CtQ Pilot Program
Henderson, Nevada – December 4, 2017 –United Health Products, Inc. (UHP) (OTC: UEEC), manufacturer and marketer of HemoStyp®, a patented hemostatic gauze for the healthcare and wound care sectors, today announced that it is proceeding with its application for HemoStyp under the FDA’s new and innovative CtQ Pilot Program. The FDA selected UHP’s HemoStyp as only one of nine participants for the program. UHP management has scheduled its first face-to-face meeting with FDA experts for January 17, 2018 to provide the agency with whatever information it needs to advance the application for premarket approval (PMA).
The FDA has stated that it intends to work collaboratively with pilot program participants during the review of their PMA submission to define characteristics of the device that are critical to product quality, and how these characteristics are controlled in design and manufacturing prior to the postmarket inspection. For pilot program participants, the FDA would forego conducting the standard PMA preapproval inspection, and a postmarket inspection focusing on the PMA applicant’s implementation of the critical to quality characteristics would be conducted instead.
The CtQ Pilot Program was created to identify products that have a chemical makeup of demonstrated safe interaction with the body –as evidenced by years of prior product usage and studies-- to be approved for Class III internal surgical use. The program’s intent is to allow products that have demonstrated repeated safe interaction to enter the market in a more efficient manner. This application will run simultaneously with the company’s prior Class II application for expanded indication. The market for 2017 internal surgical market for hemostatic products is estimated at in excess of seven billion dollars, and is expected to grow at 7.1% over the next few years, to reach more than $8.3 billion by 2022. (http://industryarc.com/Report/15189/hemostats-market.html)
Concurrent with its CtQ Pilot Program participation, UHP reaffirms that its current Class II application – Expanded Indication submission with the US FDA-- continues to progress, and is in an advanced stage of review
About Premarket Approval Application Critical to Quality (PMA CtQ) Pilot Program
Top-quality medical devices help the FDA better protect and promote public health. And one of the top priorities for FDA’s medical devices center is a focus on quality.
More specifically, the FDA is working with stakeholders—industry, health care providers, patients, payers, and investors—to build a strong Case for Quality.
This program allows the FDA to identify device manufacturers that consistently produce high-quality devices. By doing so, we can better focus our resources helping other manufacturers raise their level of quality. This program also helps the FDA identify and promote practices that support consistent quality manufacturing, and align our regulatory, enforcement, compliance approaches with those practices.
The FDA launched the Case for Quality in 2011 following an in-depth review of device quality data and feedback from both FDA and industry stakeholders. The FDA’s analysis flagged certain widespread or common manufacturing risks that impact product quality. The review also showed manufacturers that focus on and manage those risks often become more productive, receiving fewer complaints, needing to open fewer CAPAs and investigations, and having lower quality-related product costs than their competitors.
In simple terms, the review identified that an investment in quality has long-term payoffs."
Get a U-Haul from UHP 🚽headquarters🧻. It'll make you feel better because you will be visiting such a nice suite. 526 Commerce Circle, Suite 120 Mesquite, NV 89027
Specifically what have I misstated 🍭Mr. Con Man🍭? You seem to have a dislike for anyone who displays an ounce of common sense. And believe me, it doesn't take much to see through this Ponzi Scheme with the mountain of misinformation; every bit of it unverifiable. All I ever see you do is fish for suckers, groom them into your internet boiler room, defraud them, and then recruit them into the base of the Ponzi Scheme relieving them of their hard earned money..
That can be a dual edged sword depending upon what happens from here with the company.
Volume before price
We know the drill.
That write up you did on JB, pretty good. Appreciate it.
Jason going to stuff ole Georgie boy soon with Sapx:)
Thank you. I'm guessing that might be the only activity this year (although I have not been following that closely). Someone bought a lottery ticket for the future hoping someday....
First I think Wallace has to leave.
Name a single time you have been right about anything in many, many years posting about this stock. Every time I read a post by you, the exact opposite of what you are describing becomes reality.
Utter bullshit. There is no link or verification whatsoever. It is truly amazing the way you provide manufactured bullshit and attempt to pass it off as fact.
Considering the tweets, I read it as last Monday as in 2 days ago.
I read it. Pure bullshit. One of Art's all time bests, in that regard, is when he praises the work of Toshi Ando. Drugman, if you think Skwyerz is going to supplant nuclear medicine and radiopharmacies; I'll sell you the Tappan Zee bridge. I'm not saying QD's won't do it someday. I'm simply saying he won't be any more involved than he is with displays with his proclaimed industry disrupting technology. And it happening soon. Cardinal Health and GE Healthcare, among others, dominate that sector of imaging. Skwyerz is a pissant compared to them.
It isn't from the internet. I did an exhaustive search using multiple engines. If it is real, it is an internal document. Even if it is real, it wasn't released as stated so something obviously changed.
I'm skeptical, not just of the release in the post, but of everything given the history.
UHP Headquarters: 526 Commerce Circle, Suite 120 Mesquite, NV 89027 Try and find office space. I cannot. Is there anything more than a PO Box? Zoom in on the map view and it shows building numbers. This appears to be a local U-Haul dealer using the building. You can click on different building and check the photos too. It calls this headquarters on the UHP website. And this so-called "company" is going to compete with J&J Surgicell and Phizer Oxycel among others? No wonder there have never been any sales.